

## A channelopathy mutation in the voltage-sensor discloses contributions of a conserved phenylalanine to gating properties of Kv1.1 channels and ataxia

Sonia Hasan<sup>1,+</sup>, Cecilia Bove<sup>2,+</sup>, Gabriella Silvestri<sup>3</sup>, Elide Mantuano<sup>4</sup>, Anna Modoni<sup>3</sup>, Liana Veneziano<sup>4</sup>, Lara Macchioni<sup>2</sup>, Therese Hunter<sup>5</sup>, Gary Hunter<sup>5</sup>, Mauro Pessia<sup>2,5</sup>, Maria Cristina D'Adamo<sup>5,\*</sup>




Figure S1: Time course of Kv1.1 expression. Oocytes were depolarized from a holding potential of -80mV to a voltage of +60mV for 500ms. Current amplitudes were plotted as a function of days after oocytes were injected. The data points are mean  $\pm$  SE of 10 cells.




Figure S2: Effect of mutation on slow inactivation. Normalized and overlaid current traces showing the slow inactivation time course for the indicated channels. The membrane potential of oocytes were held at -80 mV and current traces were evoked by depolarizations at +60 mV for 3.5min.  $I_{peak}$  is the instantaneous current whereas  $I_{final}$  is the current amplitude measured at the end of the depolarizing step. The traces were fitted with two exponential functions and no statistical differences were found in either  $\tau_{fast}$  or  $\tau_{slow}$  of all channel types (data not shown).

Kv1.1	1	mtvmsgenvdeasaapghpqdgsyprqadhdheccervvinisglrfet	50
Kv1.2	1	mtvatgdpvdeaaaalpghpqd-tydpea---dheccervvinisglrfet	46
Kv1.1	51	qlktlaqfpntllgnpkkrmyfdplrneyffdrnrpsfdailyyyqsgg	100
Kv1.2	47	qlktlaqfpetllgdpkkrmyfdplrneyffdrnrpsfdailyyyqsgg	96
Kv1.1	101	rlrrpvnvpldmfseeikfyelgeeamekfredegfikkeerplpekeyq	150
Kv1.2	97	rlrrpvnvpldifseeirfyelgeeamekfredegfikkeerplpenefq	146
Kv1.1	151	rqvllfeypessgparviaiavsvmilisivifcletlpelkdd-kdft	199
Kv1.2	147	rqvllfeypessgpariaiaivsvmilisivsfletlpifrdenedmh	196
Kv1.1	200	g---tvhridnttviy-nsniftdpffivetlciwfsfelvvrffacps	245
Kv1.2	197	ggvtfhtysnstigyqqsftdpffivetlciwfsfeflvvrffacps	246
Kv1.1	246	ktdffknimnfidivaiipyfitlgtetaeq-egnkgeqatslailrvi	294
Kv1.2	247	kagfftnimniidivaiipyfitlgtelaekpedaqqqqamslailrvi	296
Kv1.1	295	rlrvvfrifklshrskglqilgqtlkasmrelgllifflfigvilfssav	344
Kv1.2	297	rlrvvfrifklshrskglqilgqtlkasmrelgllifflfigvilfssav	346
Kv1.1	345	yfaeaaeaeshfssipdafwvavsmttvgygdmypvtiggkivgslcai	394
Kv1.2	347	yfaeaderdsqfipsipdafwvavsmttvgygdmvpttiggkivgslcai	396
Kv1.1	395	agvltialpvpvivsnfnyfyhreteegeeqaqlhvss-pnlasdsdlsr	443
Kv1.2	397	agvltialpvpvivsnfnyfyhreteegeeqaqlqvtsckipsspdlkk	446
Kv1.1	444	-rssstmskseymeieedmnnsiahyrqvnirtancttanqncvnkskll	492
Kv1.2	447	rsastisksdymeieqgvnnsnedfreenlktanctlanctnyvntkml	496
Kv1.1	493	tdv	495
Kv1.2	497	tdv	499

Figure S3: Human Kv1.1 protein sequence aligned with rat Kv1.2. Alignment was performed using EMBOSS<sup>1</sup> Needle alignment program. Kv1.1 F303 and its corresponding Kv1.2 are highlighted in yellow. The L339 and I335 residues and the corresponding Kv1.2 L341 and I337 are highlighted in blue.

## Reference

1. Rice, P., Longden, I. & Bleasby, A. EMBOSS: The European Molecular Biology Open Software Suite. *Trends Genet* **16**, 276-277 (2000).